AI Article Synopsis
- Complete suppression of thromboxane A(2) (TXA2) production by aspirin is necessary for effective cardioprotection, yet variability exists in patients with coronary heart disease (CHD).
- A study involving CHD patients and healthy individuals receiving low-dose aspirin revealed that TXB2 levels varied significantly in CHD patients, indicating inconsistent inhibition of platelet cyclooxygenase-1 (COX-1) activity.
- Elevated TXB2 levels in some CHD patients suggest potential risks of inadequate aspirin response, highlighting the need for monitoring TXB2 to identify patients who may not achieve desired cardioprotection.
Article Abstract
Background And Objectives: Complete and persistent suppression of platelet thromboxane (TX) A(2) biosynthesis by aspirin is mandatory to fulfill its cardioprotection. We explored the determinants of heterogeneity of TXB2 generation in clotting whole blood, a capacity index of platelet cyclooxygenase (COX) activity, in patients with coronary heart disease (CHD) versus healthy subjects treated with low-dose aspirin on a long-term basis.
Methods: We studied 30 patients with CHD (ie, chronic stable angina, unstable angina, and acute myocardial infarction) and 10 healthy subjects, who were treated with low-dose aspirin (100 mg daily) on a long-term basis, 12 hours after the administration of 160 mg aspirin to ensure saturation of platelet COX-1 activity. Serum TXB2 levels were assessed. The contribution of blood COX-2 to TXA2 biosynthesis was explored by evaluation of the effect of a selective COX-2 inhibitor (L-745,337) added to heparinized whole blood stimulated with Ca++ ionophore A23187 (20 micromol/L) for 1 hour or lipopolysaccharide (0.1 microg/mL) for 4 hours.
Results: In healthy subjects serum TXB2 levels ranged from 0.6 to 7.9 ng/mL (median, 2.1 ng/mL; mean +/- SD, 3.2 +/- 2.6 ng/mL). In CHD patients we detected enhanced variability in serum TXB2 generation (median, 3.1 ng/mL [range, 0.15-47 ng/mL]; mean, 8.5 +/- 12.3 ng/mL), which in 8 patients (27%) exceeded the mean value + 2 SDs detected in healthy subjects (ie, 8.4 ng/mL), set as the limit value for an adequate inhibition of platelet COX-1 by aspirin. Elevated whole-blood TXB2 generation was not dependent on leukocyte count, COX-2 activity, or cigarette smoking but was plausibly a result of defective suppression of platelet COX-1 activity.
Conclusions: Heterogeneity in the suppression of platelet COX-1 activity by aspirin occurred in CHD patients. The measurement of the serum TXB2 level seems to be an appropriate biomarker to identify patients who have an inadequate inhibition of platelet COX-1 activity by aspirin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clpt.2006.04.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention.
Front Pharmacol
December 2024
Systems Pharmacology and Translational Therapeutics Laboratory, The Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University, Chieti, Italy.
Inflammation plays a critical role in the pathogenesis of various diseases by promoting the acquisition of new functional traits by different cell types. Shared risk factors between cardiovascular disease and cancer, including smoking, obesity, diabetes, high-fat diet, low physical activity, and alcohol consumption, contribute to inflammation linked to platelet activation. Platelets contribute to an inflammatory state by activating various normal cells, such as fibroblasts, immune cells, and vascular cells.
View Article and Find Full Text PDFA sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα.
Front Pharmacol
November 2024
Systems Pharmacology and Translational Therapeutics Laboratory, at the Center for Advanced Studies and Technology (CAST), and Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University, Chieti, Italy.
Background: PPARα and cyclooxygenase (COX)-2 are overexpressed in certain types of cancer. Thus, developing a dual inhibitor that targets both could be more effective as an anticancer agent than single inhibitors. We have previously shown that an analog of the bezafibrate named AA520 is a PPARα antagonist.
View Article and Find Full Text PDF[Antithrombotic Action of Alcohol in Relation to Platelet Function].
Nihon Eiseigaku Zasshi
December 2024
Department of Preventive Medicine, Hyogo Medical University Faculty of Medicine.
The relationship between alcohol consumption and incident ischemic heart disease and stroke is characterized by a J- or U-shape. This denotes that light drinking has a preventive effect on cardiovascular diseases. Effects of alcohol drinking on lipid metabolism including an increase in HDL cholesterol concentration and a decrease in LDL cholesterol concentration are the main reasons for the anti-atherosclerotic action of alcohol.
View Article and Find Full Text PDFA Review of Platelet-Rich Plasma Use in Patients Taking Non-steroidal Anti-inflammatory Drugs for Guideline Development.
Cureus
October 2024
Orthopaedic Surgery, Desert Orthopaedic Center, Las Vegas, USA.
Platelet-rich plasma (PRP) is an autologous blood product containing concentrated platelets, growth factors, and anti-inflammatory cytokines that promote healing and regeneration. Platelets release active components through a degranulation process, which is inhibited by certain nonsteroidal anti-inflammatory drugs (NSAIDs). Current deferral guidelines are not established, but NSAIDs are expected to have a time-dose relationship with platelet inhibition.
View Article and Find Full Text PDFThe role of the cyclooxygenase-2 pathway in tissue ischemia and revascularization following skeletal muscle injury induced by bothropic snake venom.
Microvasc Res
January 2025
Departamento de Farmacologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, SP, Brazil. Electronic address:
Bothrops asper venom (Bav) contains metalloproteinases that disrupt the microvascular system, impairing muscle tissue regeneration after injury. This study investigated the impact of the cyclooxygenase-2 (COX-2) pathway on vascular injury and revascularization in muscle injuries induced by Bav. Mice were injected with Bav into the gastrocnemius muscle and treated with lumiracoxib, a selective COX-2 inhibitor, 30 min, 2 days, and 6 days post-Bav injection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!